Evidence map›Paper›PMID 42548585›Full record

ArticleFrontiers in oncology2026

STMN1 expression is associated with chemotherapy and immunotherapy efficacy in biliary tract cancer.

Changcheng Wang, Lingxi Nan, Qingyang Meng, Chengjia Lu, Wenkai Cui, Tao Suo, Shulong Zhang, Houbao Liu, Yueqi Wang, Wenqing Qiu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Changcheng Wang *Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Lingxi Nan *Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qingyang Meng *Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Chengjia LuDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenkai CuiDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Tao SuoDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Shulong ZhangDepartment of General Surgery, Central Laboratory, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
Houbao LiuDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yueqi WangDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenqing QiuDepartment of General Surgery, Central Laboratory, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
Xiaobo BoDepartment of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The prognostic role of STMN1 and its regulatory effects on the tumor microenvironment (TME) in biliary tract cancer (BTC) remain poorly defined. This study aimed to investigate the prognostic value of STMN1 and its predictive capacity for chemotherapy and immunotherapy responses among patients with BTC. Methods: Six independent cohorts encompassing tissue microarray specimens and transcriptional profiling data from BTC patients were included in our analysis. STMN1 protein expression was quantified via immunohistochemistry (IHC) on tissue microarrays. Results: STMN1 expression was significantly correlated with inferior overall survival (OS). Multivariate regression further identified STMN1 as an independent adverse prognostic biomarker for OS. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) revealed that elevated STMN1 expression was tightly linked to immune response activation and T-cell infiltration, enabling the formation of an immune-inflamed TME in BTC. IHC validation confirmed positive correlations between STMN1 levels and anti-tumor CD8⁺ T-cell infiltration as well as programmed death-ligand 1 (PD-L1) expression. Patients with low STMN1 expression derived prominent survival benefits from gemcitabine-based adjuvant chemotherapy (ACT), whereas high STMN1 expression predicted superior therapeutic responses to immune checkpoint blockade (ICB) in BTC recipients. Discussion: STMN1 functions as an independent prognostic biomarker and differential predictive indicator for ACT and ICB efficacy in BTC, likely facilitating the construction of an immune-inflamed TME by promoting tumor immune cell recruitment and infiltration.

Indexed as

biliary tract cancerimmunotherapyprognosisSTMN1tumor immune

Identifiers

PMID42548585
PMCPMC13429508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.